| 0.3216 0.022 (7.34%) | 08-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.43  |
1-year : | 0.53 |
| Resists | First : | 0.37 |
Second : | 0.45 |
| Pivot price | 0.31 |
|||
| Supports | First : | 0.25 | Second : | 0.2 |
| MAs | MA(5) : | 0.3  |
MA(20) : | 0.33 |
| MA(100) : | 0.36 |
MA(250) : | 1.24 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 35.3 |
D(3) : | 32.3 |
| RSI | RSI(14): 46.8 |
|||
| 52-week | High : | 3.04 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MDCX ] has closed below upper band by 47.2%. Bollinger Bands are 21.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.33 - 0.33 | 0.33 - 0.33 |
| Low: | 0.31 - 0.31 | 0.31 - 0.31 |
| Close: | 0.32 - 0.32 | 0.32 - 0.32 |
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Mon, 03 Aug 2026
Medicus' chief medical officer is set to lead its UK subsidiary Aug. 30 - Stock Titan
Fri, 31 Jul 2026
About 84 Women, Four Groups: Teverelix Endometriosis Trial - Stock Titan
Mon, 27 Jul 2026
FDA Recommends Two-Year Follow-Up for Gorlin Syndrome Study - Stock Titan
Wed, 06 May 2026
Medicus Pharma Announces Results from Pre-Specified - GlobeNewswire
Fri, 24 Apr 2026
Medicus Pharma receives Nasdaq notice for minimum bid price non-compliance - Investing.com
Thu, 23 Apr 2026
Medicus Pharma Ltd May Offer And Sell Common Shares Up To $50 Million Aggregate Through Agents - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 5.038e+007 (%) |
| Held by Institutions | 12.4 (%) |
| Shares Short | 1,930 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -278.2 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.15 |
| Dividend | 0 |
| Forward Dividend | 2.84e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|